Patents Assigned to Serenium, Inc.
  • Publication number: 20200163599
    Abstract: A cloud based pulse oximetry system and method is provided that incorporates both a software and hardware component. The hardware component includes a limited use pulse oximetry probe having an energy source and data transmitting capabilities. The probe houses a light source and a light detector that compare and calculate the differences in the oxygen-rich versus oxygen-poor hemoglobin in the body part to which, it is attached. Data from the probe is collected, analyzed, and communicated using a cloud based computing system. The system may be used for collecting and analyzing pulse oximetry data for any medical need such as diagnosis of obstructive sleep apnea.
    Type: Application
    Filed: September 19, 2016
    Publication date: May 28, 2020
    Applicant: Serenium, Inc.
    Inventors: David Gozal, David Rosen, Michael Cory Zwerling
  • Publication number: 20180353126
    Abstract: One aspect of the present invention is to assess the performance of automated analysis of blood oxygen saturation (SpO2) recordings as a screening tool for OSAHS. As an initial step, statistical, spectral and nonlinear features are estimated to compose an initial feature set. Then, a fast correlation-based filter (FCBF) is next applied to search for the optimum subset. Finally, the discrimination power (OSAHS negative vs. OSAHS positive) of three pattern recognition algorithms is assessed: linear discriminant analysis (LDA), quadratic discriminant analysis (QDA) and logistic regression (LR). According to another aspect of the invention, oximetry is used to determine the OSAHS severity in children. For testing the severity of OSAHS, first spectral analysis is conducted to define and characterize a frequency band of interest in SpO2.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 13, 2018
    Applicant: Serenium, Inc.
    Inventors: David Gozal, Leila Gozal
  • Publication number: 20180340226
    Abstract: It was determined that plasma-derived exosomes from either obese (OB) or obstructive sleep apnea (OSA) children with evidence of endothelial dysfunction (ED). Such ED exosomes lead to up-regulation of adhesion molecules in endothelial cells. Exosomal miRNA cargo differences underlie the mechanisms accounting for the presence of ED. Specifically, expression of miRNA-630 is reduced in circulating exosomes of either obese or OSA children with ED, and normalizes in OSA children with ED after treatment along with restoration of endothelial function. These findings elucidate a novel role of exosomal miRNA-630 as a putative key mediator of vascular function and a biomarker of cardiovascular disease (CVD) risk in children.
    Type: Application
    Filed: August 22, 2016
    Publication date: November 29, 2018
    Applicant: Serenium, Inc.
    Inventors: David Gozal, Leila Gozal